Gate Bioscience Inc, a US company founded in 2021 to develop small molecule drugs targeting disease-causing extracellular proteins, has received $65 million in Series B financing to take its lead programmes into clinical development. This brings total capital raised for the company to $135 million. The financing was led by Forbion of the Netherlands with Eli Lilly and Co as a new investor.
Artios Pharma Ltd, a UK clinical-stage company with products to kill cancer cells by blocking their ability to repair damaged DNA, has raised $115 million in an oversubscribed Series D financing. The round was co led by founding investor SV Health Investors and new investor RA Capital Management. The funds will be used to advance two small molecule drugs against large cancers. The first, alnodesertib, is an inhibitor of the ATR protein which is involved in DNA repair, and the second is ART6043, an inhibitor of the DNA repair enzyme DNA polymerase theta (Pol theta).
BC Platforms AG, one of the healthcare industry’s largest data management and analytics companies, has launched a new technology platform that features artificial intelligence as its core component. This comes at a time when AI is being applied across drug discovery in order to help researchers analyse large datasets and identify potential drug targets. The Switzerland-based company says that its new technology takes AI one step further by linking drug discovery and development data to real-world evidence.
Drug Discovery
Stroke research progresses towards new frontier
By Marc Dechamps
Research Strategy
Redefining drug discovery using quantum physics
By Jarryl D'Oyley and Catherine Stace
Regulation and Policy
Natural history studies underpin clinical research
By Femida Gwadry-Sridhar
Public Policy
EU pharma reform meets US MFN pricing
By Maarten Meulenbelt
Stock Market Performance
Q3 sees unexpected recovery in stocks
By Robin Davison
